Actemra actpen 162 MG/0.9 ML 0.9ML
Ended Awarded Last action
- Contract number
- SPE2DR26FNR0M
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $75,687
Award facts
- Contract value 100% obligated
- $75,686.52 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $75,686.52 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 mL auto-injectors on January 6, 2026, with completion expected by January 7, 2026. This is a non-set-aside, competitively awarded contract with performance occurring at the contractor's headquarters in Conshohocken, Pennsylvania. The delivery order is issued under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00 between DLA Troop Support Medical and AmerisourceBergen (through its parent company Cencora, Inc.), which serves as a comprehensive global pharmaceutical support vehicle through December 2026.
AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., is a major pharmaceutical distributor and critical federal medical procurement vendor that supplies brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to military and veteran healthcare systems. The parent IDC with DLA enables the company to fulfill diverse pharmaceutical needs across the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide. Actemra (tocilizumab) is a biologic immunosuppressant commonly used in the treatment of rheumatoid arthritis and other inflammatory conditions, reflecting the scope of specialty pharmaceuticals distributed through this contract vehicle.
Quick answers
Who was awarded contract SPE2DR26FNR0M?
SPE2DR26FNR0M was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 6, 2026.
How much is contract SPE2DR26FNR0M worth?
The government has obligated $75,687 on SPE2DR26FNR0M.
Is contract SPE2DR26FNR0M an order under another contract?
Yes. SPE2DR26FNR0M is a delivery order under SPE2DR25D1021, an indefinite delivery contract.
Was contract SPE2DR26FNR0M competed?
The extent of competition for SPE2DR26FNR0M was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award